Healthcare / Medical Instruments & SuppliesKuala Lumpur
$0.14
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 26% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-19.5M · quality 56.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
15/100
F
Piotroski
6/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
8/100
SEC 0%
Sin guardar todavía.
Market Cap
$84M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-25.8%
↓Gross Margin
-36.5%
↓Debt/Equity
1.05
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2024–2025 · 1 años de histórico normalizado
Revenue CAGR
+9.7%
FCF CAGR
—
FCF margin
-54.2%
FCF / Net income
0.61x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $35.5M · net income $-31.6M · FCF $-19.2M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 |
|---|---|---|---|
| Income Statement | |||
| Revenue | $35.5M | $35.5M | $32.3M |
| Net Income | $-31.6M | $-31.6M | $-46.3M |
| EBITDA | $-16.6M | $-16.6M | $-28.9M |
| EPS | -0.06 | -0.06 | -0.11 |
| Gross Margin | -36.5% | -36.5% | -78.0% |
| Operating Margin | -73.2% | -73.2% | -121.0% |
| Net Margin | -89.2% | -89.2% | -143.2% |
| Balance Sheet | |||
| Debt/Equity | 1.05 | 1.05 | 1.26 |
| Current Ratio | 0.89 | 0.89 | — |
| Cash Flow | |||
| Free Cash Flow | $-19.2M | $-19.2M | $-19.7M |
| Returns | |||
| ROE | -25.8% | -25.8% | -42.6% |
| Valuation | |||
| P/B | 0.64 | 0.64 | 1.13 |
| Growth & Yield | |||
| Revenue Growth | 9.7% | 9.7% | — |
| EPS Growth | 47.9% | 47.9% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-19.4%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.11 → -0.06
Residual
-19.4%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.